Rosetta Genomics, Ltd. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2016. For the quarter, the company reported revenues decreased 10% to $2.2 million compared to $2.4 million for the third quarter of 2015, primarily due to lower sales of urologic and solid tumor testing services as the company refocused its sales force on the Reveal introduction. Operating loss was $3.9 million compared with $3.9 million for the third quarter of 2015. Net loss was $4.0 million or $0.19 per basic and diluted ordinary share compared to $3.9 million or $0.27 per basic and diluted ordinary share for the same period a year ago. On a non-GAAP basis, net loss was $3.7 million or $0.18 per ordinary share compared to $3.7 million or $0.25 per ordinary share for the same period a year ago. For nine months, the company reported revenues increased 53% to $7.2 million compared to $4.7 million for the first nine months of 2015. Operating loss was $11.3 million compared to $10.6 million for the same period a year ago. Net loss was $11.4 million or $0.55 per basic and diluted ordinary share compared to $10.6 million or $0.76 per basic and diluted ordinary share for the same period a year ago. On a pro forma basis (as if the PersonalizeDx acquisition occurred on January 1, 2015 instead of the actual acquisition date of April 13, 2015), revenues for the first nine months of 2016 increased 9% compared with pro forma revenues of $6.6 million for the first nine months of 2015.